Phase III clinical trial of the vaccine candidate Abdala began in Cuba.
CCBYOpen access
Rapid response to:
Research
Excess mortality in Wuhan city and other parts of China during the three months of the covid-19 outbreak: findings from nationwide mortality registries
Phase III clinical trial of the vaccine candidate Abdala began in Cuba.
Dear Editor
The vaccine candidate Abdala, from the Center for Genetic Engineering and Biotechnology (CIGB), is positioned as the second specific Cuban immunogen against SARS-CoV-2 that goes to phase III of clinical trials, after the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) will approve the change of stage according to the established regulations.
Abdala is a specific vaccine against Sars-CoV-2 that has been developed by the CIGB and in collaboration with Aica Labs we have managed to turn it into that bulb that we have been able to appreciate today. The protein that composes it has been modeled by our bioinformatic scientists in our laboratories. It is formed by the receptor-binding domain, which is responsible for infecting human cells in the individual. This protein has been widely used for vaccine candidates, regardless of the technological platform used. In this case, Abdala uses the smallest portion of the spike protein, or protein S, responsible for the spread of the virus.
This antigen has the characteristic that, because it is expressed in the pichia pastori yeast cell, it also has modifications that move it evolutionarily away from the molecule as seen in the virus and that it infects. This then makes it a very attractive molecule, from the antigenic point of view, in order to obtain high levels of immune response in individuals. This protein binds to a well-known immunological adjuvant such as aluminum hydroxide, “which is used in many vaccines that have already been tested and are widely used in humans. "The union of these two components is what makes us have this vaccine candidate, which is administered intramuscularly.
Kind Regards.
Competing interests:
No competing interests
22 March 2021
Odalys Rodriguez Guillen
Doctor
Dr. Grace Alicia De Lara Garcia, Lic Ana Cecilia Hernandez Rendon, Madelaine Veronica Fernandez Garcia, Dr. Mercedes De leon Castillo, Dr. María Eugenia Bravo Rodríguez, Dr Lidia De la cruz Perez, Lic. Maebis Fernadez Leiva, Dr. Marlene Ramirez Gonzalez, Lic. Yousy Ortega Leon, MSc. Ihosvany Castellanos Santos
Rapid Response:
Phase III clinical trial of the vaccine candidate Abdala began in Cuba.
Dear Editor
The vaccine candidate Abdala, from the Center for Genetic Engineering and Biotechnology (CIGB), is positioned as the second specific Cuban immunogen against SARS-CoV-2 that goes to phase III of clinical trials, after the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) will approve the change of stage according to the established regulations.
Abdala is a specific vaccine against Sars-CoV-2 that has been developed by the CIGB and in collaboration with Aica Labs we have managed to turn it into that bulb that we have been able to appreciate today. The protein that composes it has been modeled by our bioinformatic scientists in our laboratories. It is formed by the receptor-binding domain, which is responsible for infecting human cells in the individual. This protein has been widely used for vaccine candidates, regardless of the technological platform used. In this case, Abdala uses the smallest portion of the spike protein, or protein S, responsible for the spread of the virus.
This antigen has the characteristic that, because it is expressed in the pichia pastori yeast cell, it also has modifications that move it evolutionarily away from the molecule as seen in the virus and that it infects. This then makes it a very attractive molecule, from the antigenic point of view, in order to obtain high levels of immune response in individuals. This protein binds to a well-known immunological adjuvant such as aluminum hydroxide, “which is used in many vaccines that have already been tested and are widely used in humans. "The union of these two components is what makes us have this vaccine candidate, which is administered intramuscularly.
Kind Regards.
Competing interests: No competing interests